 SOUTH SAN FRANCISCO, Calif., March 24, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that it will host a virtual investor event at 1:00 p.m. 3:00 p.m. ET 10:00 a.m. 12:00 p.m. PT on Wednesday, April 7, 2021. 